Article Text

SP0124 Advances in the Treatment of Spondyloarthritis
  1. M. V. Navarro Compán1,2
  1. 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands
  2. 2Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain


Spondyloarthritis (SpA) is a group of chronic inflammatory disease with either predominantly axial symptoms of the spine and sacroiliac joints (axial SpA) or predominantly arthritis (peripheral SpA), being anlylosing spondylitis the major subgroup.

The management of ankylosing spondylitis and other SpA such as psoriatic arthritis (PsA) is becoming more and more complex due to major progress in the last years. Nonsteroidal anti-inflammatory drugs (NSAIDs) are recommended as first stage in axial SpA and new studies have shown that continuous NSAID use revert the effects of inflammation on radiographic progression. The treatment with disease-modifying drugs, such as methotrexate, sulfasalazine, leflunomide, should be considered at an early stage in PsA and in combination with biologic therapies in case of inadequate response. Remarkable advances in axial and peripheral SpA are the development of new biologic therapies as well as their optimization and an early use of these drugs. Non-pharmacological treatment has also a positive effect on pain, mobility and function. In order to provide the best care to SpA patients, primary physicians should have knowledge about the different options and the best way to manage these patients.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.